Safety of intravenous iron in hemodialysis patients-Reference-Cited by-同舟云学术

Safety of intravenous iron in hemodialysis patients

Published:2017-04 Issue: Volume:21 Page:S93-S103
ISSN:1492-7535
Container-title:Hemodialysis International
language:en
Short-container-title:Hemodialysis International

Author:

Li Xiaojuan¹²,Kshirsagar Abhijit V.²,Brookhart M. Alan¹

Affiliation:

1. Department of Epidemiology; University of North Carolina at Chapel Hill; Chapel Hill North Carolina USA

2. UNC Kidney Center; University of North Carolina at Chapel Hill; Chapel Hill North Carolina USA

Funder

Korea National Institute of Health

National Institute of Diabetes and Digestive and Kidney Diseases

National Research Service Award Institutional Research Training

National Institutes of Health

Publisher

Wiley

Subject

Nephrology,Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hdi.12558/fullpdf

Reference77 articles.

1. Anemia of end-stage renal disease;Eschbach;Kidney Int.,1985

2. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%;Collins;J Am Soc Nephrol.,2001

3. Iron dosing in kidney disease: Inconsistency of evidence and clinical practice;Gaweda;Nephrol Dial Transplant.,2015

4. Iron management in chronic kidney disease: Conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) controversies conference;Macdougall;Kidney Int.,2016

5. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin;Kapoian;J Am Soc Nephrol.,2008

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The treatment effects and cardiovascular events of high-dose intravenous iron for hemodialysis patients with renal anemia: A systematic review and meta-analysis;Chronic Illness;2023-06-07

2. The Switch from Ferric Gluconate to Ferric Carboxymaltose in Hemodialysis Patients Acts on Iron Metabolism, Erythropoietin, and Costs: A Retrospective Analysis;Medicina;2023-06-02

3. Iron Supplements Concomitant within Hypoxia-Inducible Factor Prolyl Hydroxylase Domain Inhibitors in the Treatment of Chronic Kidney Disease Anemia;Kidney Diseases;2023

4. Plasma Non-transferrin-Bound Iron Could Enter into Mice Duodenum and Negatively Affect Duodenal Defense Response to Virus and Immune Responses;Biological Trace Element Research;2022-03-16

5. Iron Therapy in Chronic Kidney Disease: Days of Future Past;International Journal of Molecular Sciences;2021-01-20